AbbVie and Regenxbio Inc entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, which would give the latter an upfront payment of $370 million.
Regenxbio may potentially receive up to $1.38 billion in milestone payments, the pharmaceutical companies said on Monday.
RGX-314 is currently in a pivotal trial for the treatment of wet age-related macular degeneration (AMD), an eye disorder causing blurred vision or a blind spot in the visual field. The trial is testing RGX-314 delivered under the retina.
It is also being studied in patients with wet AMD and diabetic retinopathy in two separate mid-stage clinical trials using a different type of delivery.
Regenxbio will be responsible for the completion of the ongoing studies of RGX-314. Both companies will share the costs of additional trials of RGX-314, they said.
AbbVie will lead the clinical development and commercialization of RGX-314 globally.
https://finance.yahoo.com/news/1-abbvie-regenxbio-enter-deal-111343174.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.